{"success":true,"data":{"pressRelease":{"id":"22215","rtpr_id":"nGNX1LBPjN","ticker":"ALDX","exchange":"NASDAQ","all_tickers":["ALDX"],"title":"INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Aldeyra Therapeutics, Inc. Of Class Action Lawsuit and Upcoming Deadlines – ALDX","author":"Globe Newswire","published_at":"2026-05-05T21:06:38.106Z","article_body":"NEW YORK, May 05, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a\nclass action lawsuit has been filed against Aldeyra Therapeutics, Inc.\n(“Aldeyra” or the “Company”) (NASDAQ: ALDX).   Such investors are\nadvised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980,\n(or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are\nencouraged to include their mailing address, telephone number, and the number\nof shares purchased. \n\nThe class action concerns whether Aldeyra and certain of its officers and/or\ndirectors have engaged in securities fraud or other unlawful business\npractices. \n\nYou have until May 29, 2026, to ask the Court to appoint you as Lead Plaintiff\nfor the class if you purchased or otherwise acquired Aldeyra securities during\nthe Class Period. A copy of the Complaint can be obtained at\nwww.pomerantzlaw.com.          \n\n[Click here for information about joining the class action]\n(https://www.globenewswire.com/Tracker?data=CKgT_5mKZxYOUCdL0GIw0DOeyjnpvx_LtxEahtGZUFKWSNAId6hqcCvAhdglj9uZNz0KDx1RlHrrHOzh1AC-t9lxrlxMRybv_bvxWVUYJGjAqAD0bvT0Esr5xkAAiLcnI1c_SA45p4vXxaupP0QMrQceiplc4W8f-Rf6SOCJbqt2qHpy3yVl2aya8Js1Ys_D)  \n\nOn March 17, 2026, Aldeyra issued a press release “announc[ing] receipt of a\nComplete Response Letter (CRL) from the U.S. Food and Drug Administration\n(FDA) for the New Drug Application (NDA) of reproxalap, an investigational\ndrug candidate, for the treatment of dry eye disease.”  According to\nAldeyra’s press release, “[t]he CRL stated that there is ‘a lack of\nsubstantial evidence consisting of adequate and well-controlled investigations\n… that the drug product will have the effect it purports or is represented\nto have under the conditions of use prescribed, recommended, or suggested in\nits proposed labeling’ and that ‘the application has failed to demonstrate\nefficacy in adequate and well controlled studies in the treatment of signs and\nsymptoms of dry eye disease.’  The letter also stated that the\n‘inconsistency of study results raises serious concerns about the\nreliability and meaningfulness of the positive findings’ and that the\n‘totality of evidence from the completed clinical trials does not support\nthe effectiveness of the product.’” \n\nOn this news, Aldeyra’s stock price fell $2.99 per share, or 70.69%, to\nclose at $1.24 per share on March 17, 2026.\n\nPomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris,\nand Tel Aviv, is acknowledged as one of the premier firms in the areas of\ncorporate, securities, and antitrust class litigation. Founded by the late\nAbraham L. Pomerantz, known as the dean of the class action bar, Pomerantz\npioneered the field of securities class actions. Today, more than 85 years\nlater, Pomerantz continues in the tradition he established, fighting for the\nrights of the victims of securities fraud, breaches of fiduciary duty, and\ncorporate misconduct. The Firm has recovered numerous multimillion-dollar\ndamages awards on behalf of class members. See www.pomlaw.com. \n\nAttorney advertising.  Prior results do not guarantee similar\noutcomes.    \n\nCONTACT: \nDanielle Peyton \nPomerantz LLP \ndpeyton@pomlaw.com \n646-581-9980 ext. 7980 \n\n\n\nGlobeNewswire, Inc. 2026","article_body_html":"","raw_payload":{"data":{"id":"nGNX1LBPjN","title":"INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Aldeyra Therapeutics, Inc. Of Class Action Lawsuit and Upcoming Deadlines – ALDX","author":"Globe Newswire","ticker":"ALDX","created":"2026-05-05T21:06:38.106Z","tickers":["ALDX"],"exchange":"NASDAQ","article_body":"NEW YORK, May 05, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a\nclass action lawsuit has been filed against Aldeyra Therapeutics, Inc.\n(“Aldeyra” or the “Company”) (NASDAQ: ALDX).   Such investors are\nadvised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980,\n(or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are\nencouraged to include their mailing address, telephone number, and the number\nof shares purchased. \n\nThe class action concerns whether Aldeyra and certain of its officers and/or\ndirectors have engaged in securities fraud or other unlawful business\npractices. \n\nYou have until May 29, 2026, to ask the Court to appoint you as Lead Plaintiff\nfor the class if you purchased or otherwise acquired Aldeyra securities during\nthe Class Period. A copy of the Complaint can be obtained at\nwww.pomerantzlaw.com.          \n\n[Click here for information about joining the class action]\n(https://www.globenewswire.com/Tracker?data=CKgT_5mKZxYOUCdL0GIw0DOeyjnpvx_LtxEahtGZUFKWSNAId6hqcCvAhdglj9uZNz0KDx1RlHrrHOzh1AC-t9lxrlxMRybv_bvxWVUYJGjAqAD0bvT0Esr5xkAAiLcnI1c_SA45p4vXxaupP0QMrQceiplc4W8f-Rf6SOCJbqt2qHpy3yVl2aya8Js1Ys_D)  \n\nOn March 17, 2026, Aldeyra issued a press release “announc[ing] receipt of a\nComplete Response Letter (CRL) from the U.S. Food and Drug Administration\n(FDA) for the New Drug Application (NDA) of reproxalap, an investigational\ndrug candidate, for the treatment of dry eye disease.”  According to\nAldeyra’s press release, “[t]he CRL stated that there is ‘a lack of\nsubstantial evidence consisting of adequate and well-controlled investigations\n… that the drug product will have the effect it purports or is represented\nto have under the conditions of use prescribed, recommended, or suggested in\nits proposed labeling’ and that ‘the application has failed to demonstrate\nefficacy in adequate and well controlled studies in the treatment of signs and\nsymptoms of dry eye disease.’  The letter also stated that the\n‘inconsistency of study results raises serious concerns about the\nreliability and meaningfulness of the positive findings’ and that the\n‘totality of evidence from the completed clinical trials does not support\nthe effectiveness of the product.’” \n\nOn this news, Aldeyra’s stock price fell $2.99 per share, or 70.69%, to\nclose at $1.24 per share on March 17, 2026.\n\nPomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris,\nand Tel Aviv, is acknowledged as one of the premier firms in the areas of\ncorporate, securities, and antitrust class litigation. Founded by the late\nAbraham L. Pomerantz, known as the dean of the class action bar, Pomerantz\npioneered the field of securities class actions. Today, more than 85 years\nlater, Pomerantz continues in the tradition he established, fighting for the\nrights of the victims of securities fraud, breaches of fiduciary duty, and\ncorporate misconduct. The Firm has recovered numerous multimillion-dollar\ndamages awards on behalf of class members. See www.pomlaw.com. \n\nAttorney advertising.  Prior results do not guarantee similar\noutcomes.    \n\nCONTACT: \nDanielle Peyton \nPomerantz LLP \ndpeyton@pomlaw.com \n646-581-9980 ext. 7980 \n\n\n\nGlobeNewswire, Inc. 2026"},"type":"article","timestamp":"2026-05-05T21:06:38.147818247Z","server_sent_at_ms":1778015198147},"received_at":"2026-05-05T21:06:38.200Z","source_url":null},"analysis":{"id":"17723","press_release_id":"22215","analysis_json":{"industry":{"label":"Pharmaceuticals, Biotechnology & Life Sciences","sector":"Health Care"},"redFlags":[],"eventType":"legal_litigation","narrative":"Pomerantz LLP issued a notice reminding investors of a class action lawsuit against Aldeyra Therapeutics regarding alleged securities fraud.\n\nThe lawsuit concerns the period surrounding the FDA's Complete Response Letter for reproxalap on March 17, 2026, which caused the stock to drop 70.69%.\n\nInvestors have until May 29, 2026, to seek lead plaintiff status; this is a solicitation by the law firm, not a new company disclosure.","sentiment":"neutral","agentHooks":{"shouldPost":false,"suggestedAngle":"Plaintiff-firm solicitation regarding prior FDA rejection -- suppress."},"keyFigures":{},"quotedText":"Pomerantz LLP announces that a class action lawsuit has been filed against Aldeyra Therapeutics, Inc. (“Aldeyra” or the “Company”)","namedEntities":{"people":[{"name":"Danielle Peyton","role":"Contact Attorney"}],"products":[],"companies":[{"name":"Aldeyra Therapeutics, Inc.","ticker":"ALDX"},{"name":"Pomerantz LLP","relationship":"plaintiff law firm"}],"dollarAmounts":[{"amount":"$2.99 per share","context":"stock price drop on March 17, 2026"}]},"materialImpact":{"score":1,"reasoning":"Plaintiff law-firm shareholder solicitation issued by Pomerantz LLP. The firm is soliciting investors to serve as lead plaintiff following a prior FDA rejection event. No new disclosure from the issuer; no certified class, no settlement."},"tickerRelevance":{"others":[],"primary":"ALDX"},"globalImportance":10,"audienceRelevance":15,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"small-cap","eventGravity":"law-firm-solicitation","triggerEvent":"prior FDA rejection (historical)","issuerAuthored":false}},"event_type":"legal_litigation","event_type_secondary":null,"sentiment":"neutral","material_impact_score":1,"narrative":"Pomerantz LLP issued a notice reminding investors of a class action lawsuit against Aldeyra Therapeutics regarding alleged securities fraud.\n\nThe lawsuit concerns the period surrounding the FDA's Complete Response Letter for reproxalap on March 17, 2026, which caused the stock to drop 70.69%.\n\nInvestors have until May 29, 2026, to seek lead plaintiff status; this is a solicitation by the law firm, not a new company disclosure.","key_figures":{},"named_entities":{"people":[{"name":"Danielle Peyton","role":"Contact Attorney"}],"products":[],"companies":[{"name":"Aldeyra Therapeutics, Inc.","ticker":"ALDX"},{"name":"Pomerantz LLP","relationship":"plaintiff law firm"}],"dollarAmounts":[{"amount":"$2.99 per share","context":"stock price drop on March 17, 2026"}]},"model_name":"glm-4.7","prompt_hash":"sha256:6c7fa2f5e3b62e83","schema_hash":"sha256:ee8f711bc9bfba0d","created_at":"2026-05-06T20:27:26.254Z","global_importance":10,"audience_relevance":15,"importance_components":{"tickerTier":"small-cap","eventGravity":"law-firm-solicitation","triggerEvent":"prior FDA rejection (historical)","issuerAuthored":false}},"durationMs":null,"modelName":"glm-4.7"}}